UroGen Pharma Q3 2026 Earnings Call - UROGEN PHARMA LTD

Financial Performance:

• Total revenue reached $89 million for Q3 2026, up significantly from $27.5 million in Q3 2025.
• Zesturi (referred to as "the story" in transcript) generated $68 million in net product revenue, representing 35% sequential growth.
• Gelmido (referred to as "gelmito" in transcript) generated $21 million in net product revenue, down from $22 million in Q2 due to a $1.5 million one-time unfavorable gross-to-net adjustment for CMS discarded drug provisions.
• Net loss narrowed to $1.5 million ($0.03 per share) compared to $33.3 million ($0.69 per share) in Q3 2025.
• Cash, cash equivalents, and marketable securities stood at $90.5 million as of September 30, 2026, including $117 million in accounts receivable.
• Cash burn included a one-time $4.8 million PDUFA fee for UGN-103 and a $4 million equity investment in Intragel Therapeutics.
• Operating expenses were $47.2 million (SG&A) and $26 million (R&D), driven by commercial spend for Zesturi and increased clinical development costs for UGN-103, UGN-104, and UGN-501.
• Interest expense was $480,000, a decrease from $3.4 million in the prior year due to refinancing, despite $75 million in additional borrowings.

Guidance and Future Outlook:

• Full-year Gelmido net product revenue guidance updated to approximately $90 million to reflect one-time adjustments and headwinds from competing clinical trials in the low-grade UTUC space.
• Full-year operating expense guidance maintained at $260 million to $270 million, with expenses expected toward the upper end.
• Company anticipates achieving profitability and generating positive cash flow in Q4 2026 using existing capital resources.
• No full-year Zesturi guidance provided due to the product being in early launch stages; full-year consensus remains a reference point.
• Long-term goal for Zesturi remains a $1.2 billion peak sales potential.
• UGN-103 launch is targeted for 2028, assuming FDA approval in mid-2027 and permanent J-code approval effective January 1, 2028.
• Direct-to-Consumer (DTC) marketing campaign for Zesturi expected to launch in mid-2027 to drive acceleration.
• Q4 revenue guidance anticipates quarter-over-quarter growth for Zesturi despite typical holiday seasonality.

Business Segments and Product Lines:

• Zesturi: FDA-approved primary surgery-free alternative for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (NMIBC).
  • Commercial metrics: 1,500+ activated accounts; 662 unique prescribers (up from 452); 331 repeat prescribers (up from 204), with repeat prescribers now representing 50% of total writers.
  • Adoption trends show a shift toward using Zesturi as primary therapy (>60% of usage) rather than adjuvant (<40%).
  • Growth driven by expanding community practices where 70% of the addressable market resides.
• Gelmido: Used for low-grade upper tract urothelial cancer (UTUC); facing headwinds from competitive Phase III trials (including UGN-104) in the low-grade space.
• UGN-103: Next-generation mitomycin formulation with NDA accepted and PDUFA goal date set for June 14, 2027.
  • Patent coverage extended to July 2044 for low-grade intermediate-risk NMIBC.
  • Plans to initiate Phase III trial for high-grade NMIBC (adjuvant) in Q4 2026.
  • Non-registrational adjuvant trial for newly diagnosed intermediate-risk patients planned.
• UGN-104: Phase III trial for low-grade UTUC progressing with enrollment completion expected by year-end or early 2027.
• UGN-501: Oncolytic virus for high-grade NMIBC; IND cleared in July, first patient dosed, with Phase I data expected in 2027.
• Strategic Collaboration: Agreement with Intragel Therapeutics provides access to biodegradable sustained-release platform (SR-gel); includes option to acquire rights to a cisplatin gel therapy for advanced head and neck cancer contingent on positive Phase II data.

Market and Competitive Landscape:

• Zesturi is the only FDA-approved primary therapy for its specific indication, offering a surgery-free alternative to repeated TURBT procedures.
• Competition for Gelmido includes multiple companies conducting trials in the low-grade UTUC space, impacting patient starts and creating revenue headwinds.
• Physician adoption is evolving from heavily pretreated patients to earlier lines of therapy as familiarity with the drug and reimbursement processes increases.
• Community urology practices are the primary site of care, accounting for the majority of utilization and representing the largest untapped opportunity.
• Market expansion planned for high-grade NMIBC and newly diagnosed populations for UGN-103.

Risks and Challenges:

• Seasonality: Summer and holiday periods historically impact patient starts and shipment volumes, though recent quarters have shown resilience.
• Reimbursement and Operational Barriers: Physician hesitation regarding reimbursement processes and workflow integration remains a key adoption hurdle.
• Clinical Trial Competition: Ongoing trials for lower-grade UTUC by other sponsors are diverting eligible patients from Gelmido.
• Launch Execution: Zesturi is in early commercial stages; growth trajectory may vary quarterly with variability in new prescriber conversion.
• Transition Risk: Managing the seamless market transition from Zesturi to UGN-103 to avoid disruption for patients.

Management Commentary and Tone:

• Tone was confident and optimistic regarding Zesturi's scaling, commercial momentum, and path to profitability.
• Management emphasized the "primary surgery-free" differentiator and increasing physician confidence as key drivers.
• Liz Barrett and Chris Degnan expressed strong conviction in the ability to reach profitability in Q4 2026.
• Mark Schoenberg highlighted clinical durability data for Gelmido and positive trial designs for UGN-103.
• Management acknowledged the "lumpy" nature of site activations but focused on the strategic shift toward driving utilization within the existing account base.

Analyst Questions and Answers:

• Patient Profiling: Urologists initially treat heavily pretreated patients but are expanding usage to patients after fewer TURBTs (even after 1 or 2 recurrences) based on claims data.
• Seasonality: Summer slowdowns impacted visit numbers but had minimal revenue impact due to strong momentum in new and repeat prescribers; Q4 expects growth despite holiday trends.
• Gelmido Long-term: Revenue expected to stabilize around $100M–$150M long-term, with potential upside if UGN-104 succeeds; current headwinds from trials are temporary.
• Zesturi Growth Drivers: Acceleration expected in 2027 via DTC campaigns and establishment of "bladder champion" roles in large group practices.
• Prescriber Metrics: Repeat prescriber rate (50%) expected to grow as operational familiarity increases; unique prescriber base (10% of target universe) has significant expansion room.
• UGN-103 Label: 12-month durability data submission does not alter review timeline; FDA has not requested additional comparative data.
• Intragel Option: Exercise of the option for the head and neck cancer asset is contingent on positive data from their Phase II study.
• Commercial Team: Current footprint of ~160 customer-facing staff is sufficient for 2027; no immediate headcount expansion planned.
• Adjuvant Data: Non-registrational adjuvant trial for UGN-103 aims to generate safety data and support guideline discussions, though not intended for label expansion.

Other Key Points:

• UGN-103 patent listing in the FDA's Orange Book provides coverage until July 2044.
• Gelmido Phase III Olympus trial 5-year follow-up showed a median duration of response of 47.8 months, with 75% of long-term follow-up patients remaining event-free.
• Management plans to submit a permanent J-code application for UGN-103 by July 1 if approved by June 14, 2027.
• The company maintains a commitment to a "primary surgery-free" value proposition across its pipeline.
• Strategic collaboration with Intragel expands capabilities into biodegradable sustained-release platforms beyond the urinary tract.